Rifaximin in Fatty Liver Disease (RiFL)

This study has been terminated.

(Review of primary endpoint data by study Investigators concluded no further patients required.)

Sponsor:

Collaborator:

National Health Service, United Kingdom

Information provided by (Responsible Party):

Imperial College London

ClinicalTrials.gov Identifier:

NCT01355575

First received: May 17, 2011

Last updated: October 16, 2012

Last verified: October 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	September 2012
Primary Completion Date:	September 2012 (Final data collection date for primary outcome measure)